IP Library Granted Patent US 11,291,676
Granted Patent B2
US 11,291,676 · App. 16/130,522 · Granted Apr 5, 2022

Composition for inhibiting immune cell proliferation comprising sialyllactose or derivative thereof and method thereof

Inventors: Siyoung Yang (Suwon-si, KR); Jimin Jeon (Daegu, KR); Li-Jung Kang (Busan, KR); Chanmi Cho (Jindo-gun, KR)
Assignee: CUPIONE CO., LTD.
A61K31/702A23L33/125A61P17/00A61P19/02A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,291,676
App. No.
16/130,522
Granted
Apr 5, 2022
Kind
B2
Abstract

Provided are a composition for inhibiting immune cell proliferation, including sialyllactose or a derivative thereof as an active ingredient, and a method of inhibiting immune cell proliferation, wherein the composition and the method may decrease expression of chemokines, decrease expression of pro-inflammatory cytokines, decrease production of inflammatory mediators, decrease expression of COX2, and decrease production of PEG 2 , and therefore, may be useful for the prevention or treatment of atopic dermatitis or arthritis.

Claims (9)

1. A method of promoting cartilage formation or inhibiting cartilage destruction in osteoarthritis, the method comprising administering a therapeutically effective amount of a composition comprising sialyllactose or a pharmaceutically acceptable salt thereof as an active ingredient to a patient in need thereof,

wherein the effective amount is determined by increased expression of type II collagen (Col2a1), increased Sox-9 activity, and/or decreased expression of matrix metalloproteinase3 (Mmp3) or matrix metalloproteinase13 (Mmp13).

2. The method of claim 1 , wherein the method has therapeutic effects on osteoarthritis.

3. The method of claim 1 , wherein the sialyllactose is 3′-sialyllactose or 6′-sialyllactose.

4. The method of claim 3 , wherein the salt of 3′-sialyllactose has a structure of the following Formula 1:

5. The method of claim 3 , wherein the salt of 6′-sialyllactose has a structure of the following Formula 2:

6. The method of claim 1 , wherein the method has one or more of the following characteristics of:

increasing Sox-9 activity; and

increasing inactivation of p-ERK.

Assignments (3)
CHANGE OF NAME Recorded Dec 31, 2020
From: SYNOVIZEN CO., LTD.
To: CUPIONE CO., LTD.
Reel/Frame 054883/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2019
From: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
To: SYNOVIZEN CO., LTD.
Reel/Frame 048725/0730 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2018
From: YANG, SIYOUNG; JEON, JIMIN; KANG, LI-JUNG; CHO, CHANMI
To: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Reel/Frame 046869/0919 →
Priority Claims (2)
KR 10-2017-0010540 · Jan 23, 2017 · national
KR 10-2017-0067915 · May 31, 2017 · national
Continuity (2)
Continuation In Part PCTKR2017010489 · Sep 22, 2017
Related Publication 20190030054A1 · Jan 31, 2019